Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Solvay Analyzing “Various Options” For Its Pharma Unit

This article was originally published in The Pink Sheet Daily

Executive Summary

Belgian firm, which co-markets TriLipix and TriCor with Abbott, confirms it is in discussions with third-parties.

You may also be interested in...



Abbott's Solvay Pharma Buy More Salve Than Cure

Abbott Laboratories announced plans to acquire Solvay's pharmaceutical business for $6.6 billion Sept. 28, a strategic maneuver that seems as much about adding revenues to Abbott's top-line as addressing long-term challenges in the pharmaceutical pipeline

Abbott's Solvay Pharma Buy More Salve Than Cure

Abbott Laboratories announced plans to acquire Solvay's pharmaceutical business for $6.6 billion Sept. 28, a strategic maneuver that seems as much about adding revenues to Abbott's top-line as addressing long-term challenges in the pharmaceutical pipeline

Abbott Buys Solvay Pharma Unit But Is It Just A Short-Term Fix?

Abbott will buy the pharma business of its Belgian-based Tricor/TriLipix partner for $6.6 billion in cash; dependence on Humira, Tricor lingers.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel